Cefaclor AF: correlation of microbiology and clinical outcome.
Cefaclor is active against Haemophilus influenzae and Moraxella catarrhalis in addition to the pathogens typically susceptible to first-generation cephalosporins. Cefaclor advanced formulation (cefaclor AF) provides the opportunity for once or twice daily dosing of this agent. Clinical trials using cefaclor AF have been carried out in a number of centres on bacterial infections of the respiratory tract, the urinary tract and the skin. In vitro susceptibility tests on selected pathogens from the clinical trials were carried out according to National Committee for Clinical Laboratory Standards recommendations, generally with excellent agreement between in vitro and in vivo response.
Thornsberry
C
C
Institute for Microbiologic Research, Franklin, TN 37064.
D001991:Bronchitis / Q000188:drug therapy; D002433:Cefaclor / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D016870:Neisseriaceae Infections / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D017192:Skin Diseases, Bacterial / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002433:Cefaclor